X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
osimertinib (428) 428
oncology (249) 249
mutation (180) 180
index medicus (176) 176
gefitinib (153) 153
lung cancer (149) 149
humans (133) 133
chemotherapy (128) 128
acquired-resistance (116) 116
open-label (107) 107
non-small cell lung cancer (106) 106
lung cancer, non-small cell (104) 104
epidermal growth factor (103) 103
azd9291 (101) 101
respiratory system (99) 99
lung neoplasms - drug therapy (92) 92
resistance (90) 90
cell lung-cancer (89) 89
nsclc (87) 87
t790m (87) 87
cancer (84) 84
carcinoma, non-small-cell lung - drug therapy (83) 83
erbb receptors - genetics (83) 83
egfr (82) 82
erlotinib (81) 81
adenocarcinoma (80) 80
tyrosine (79) 79
lung neoplasms - genetics (78) 78
1st-line treatment (74) 74
afatinib (74) 74
respiratory tract diseases (73) 73
tyrosine kinase inhibitors (71) 71
female (70) 70
carcinoma, non-small-cell lung - genetics (63) 63
patients (63) 63
epidermal growth factor receptor (61) 61
protein kinase inhibitors - therapeutic use (61) 61
genetic aspects (59) 59
non-small cell lung carcinoma (58) 58
piperazines - therapeutic use (54) 54
cancer therapies (53) 53
care and treatment (53) 53
epidermal growth factor receptors (53) 53
t790m mutation (53) 53
development and progression (52) 52
lung neoplasms - pathology (52) 52
male (52) 52
metastasis (52) 52
antineoplastic agents - therapeutic use (51) 51
mutations (50) 50
kinases (48) 48
aged (47) 47
egfr mutation (47) 47
middle aged (47) 47
neoplasms. tumors. oncology. including cancer and carcinogens (47) 47
analysis (46) 46
biopsy (43) 43
inhibitors (43) 43
carcinoma, non-small-cell lung - pathology (42) 42
therapy (42) 42
case report (40) 40
phase-iii (39) 39
multicenter (38) 38
pharmacology & pharmacy (38) 38
protein-tyrosine kinase (34) 34
tyrosine kinase inhibitor (33) 33
protein kinase inhibitors - pharmacology (32) 32
erbb receptors - antagonists & inhibitors (31) 31
brain metastases (30) 30
research (30) 30
tumors (30) 30
drug therapy (29) 29
growth-factor receptor (29) 29
health aspects (29) 29
adult (28) 28
antineoplastic agents - pharmacology (28) 28
drug resistance, neoplasm - genetics (28) 28
piperazines - pharmacology (28) 28
treatment outcome (28) 28
lung cancer, small cell (27) 27
mechanisms (27) 27
plasma (26) 26
gene mutations (25) 25
non-small-cell lung cancer (25) 25
survival (25) 25
crizotinib (24) 24
acquired resistance (23) 23
clinical trials (23) 23
drug resistance (22) 22
liquid biopsy (22) 22
original (22) 22
animals (21) 21
apoptosis (21) 21
disease progression (21) 21
biochemistry & molecular biology (20) 20
egfr mutations (20) 20
egfr-tki (20) 20
metastases (20) 20
review (20) 20
tki (20) 20
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 05/2019, Volume 30, Issue 5, pp. 839 - 844
Background: Concurrent programmed death-ligand-1 (PD-(L)1) plus osimertinib is associated with severe immune related adverse events (irAE) in epidermal growth... 
TKI | irAE | PD-1 | EGFR | osimertinib | ONCOLOGY | SAFETY | CLINICAL ACTIVITY
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 02/2019, Volume 25, Issue 3, pp. 1063 - 1069
Purpose: Tumor mutation burden (TMB) is a biomarker of response to immune checkpoint blockade (ICB). The impact of TMB on outcomes with targeted therapies has... 
CTLA-4 BLOCKADE | FACTOR-RECEPTOR GENE | GEFITINIB | CARBOPLATIN | OSIMERTINIB | ONCOLOGY | LANDSCAPE | ADENOCARCINOMA | SENSITIVITY | NEOANTIGENS | PACLITAXEL
Journal Article
Oncotarget, ISSN 1949-2553, 10/2018, Volume 9, Issue 78, pp. 34765 - 34771
Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are markedly effective for T790M-positive patients. To confer their... 
Osimertinib | T790M | Afatinib | Rebiopsy | Bevacizumab
Journal Article
Internal Medicine, ISSN 0918-2918, 2019
A 53-year-old man with advanced lung adenocarcinoma harboring epidermal growth factor receptor (EGFR) exon 19 deletion received erlotinib. After 12 months of... 
lung cancer | bevacizumab | leptomeningeal metastases | EGFR | osimertinib
Journal Article
by Liu, YT and Li, Y and Ou, QX and Wu, X and Wang, XN and Shao, YW and Ying, JM
LUNG CANCER, ISSN 0169-5002, 04/2018, Volume 118, pp. 1 - 5
Objectives: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are promising targeted therapies for EGFR-mutated non-small-cell lung... 
Resistance | Afatinib | NSCLC | ONCOLOGY | RESPIRATORY SYSTEM | Osimertinib | L718V | EGFR
Journal Article
The Oncologist, ISSN 1083-7159, 08/2019, Volume 24, Issue 8, pp. 1022 - 1026
Patients with non‐small cell lung cancer (NSCLC) treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) eventually acquire... 
ACQUIRED-RESISTANCE | AMPLIFICATION | OSIMERTINIB | THERAPY | MUTATIONS | ONCOLOGY
Journal Article
Translational Cancer Research, ISSN 2218-676X, 2017, Volume 6, Issue S1, pp. S61 - S64
Journal Article
Onkologie (Czech Republic), ISSN 1802-4475, 2017, Volume 11, Issue 2, pp. 72 - 77
Journal Article
Journal of Thoracic Disease, ISSN 2072-1439, 03/2018, Volume 10, Issue 3, pp. 1265 - 1268
Journal Article
Lung Cancer Management, ISSN 1758-1966, 12/2016, Volume 5, Issue 4, pp. 159 - 162
Dr Papadimitrakopoulou is the Jay and Lori Eisenberg Distinguished Professor of Medicine and Chief of the section of Thoracic Medical Oncology in the... 
NSCLC | osimertinib | T790M
Journal Article
Oncotarget, ISSN 1949-2553, 08/2019, Volume 10, Issue 50, p. 5152
The AXL receptor tyrosine kinase is involved in signal transduction in malignant cells. Recent studies have shown that the AXL upregulation underlies epidermal... 
Journal Article
Annals of Oncology, ISSN 0923-7534, 03/2018, Volume 29, Issue 3, pp. 687 - 693
Abstract Background Central nervous system (CNS) metastases are common in patients with non-small-cell lung cancer (NSCLC). Osimertinib has shown systemic... 
CNS | Osimertinib | Brain metastases | NSCLC | GEFITINIB | brain metastases | METASTASES | WHOLE-BRAIN RADIOTHERAPY | PHASE-2 | CELL LUNG-CANCER | THERAPY | STEREOTACTIC RADIOSURGERY | ONCOLOGY | osimertinib | RESISTANCE | INHIBITORS | ERLOTINIB
Journal Article
Internal Medicine, ISSN 0918-2918, 2017
We herein report a case of congestive heart failure which developed during osimertinib treatment. A 78-year-old woman presented with mild exertional dyspnea... 
lung cancer | heart failure | osimertinib | T790M
Journal Article
TRANSLATIONAL LUNG CANCER RESEARCH, ISSN 2218-6751, 12/2018, Volume 7, Issue Suppl 4, pp. S377 - S380
Journal Article
Clinical Lung Cancer, ISSN 1525-7304, 07/2019, Volume 20, Issue 4, pp. e492 - e494
Osimertinib is a standard treatment for ( )-mutated, -positive patients with progression during EGFR-tyrosine kinase inhibitor (TKI) therapy. Osimertinib, a... 
EGFR mutation | Osimertinib | Bevacizumab | CELL LUNG-CANCER | MULTICENTER | ONCOLOGY | ERLOTINIB
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.